Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2020 on request of the sponsor.
On 29 January 2010, orphan designation (EU/3/09/713) was granted by the European Commission to Immunomedics GmbH, Germany, for veltuzumab for the treatment of chronic lymphocytic leukaemia.
|Disease / condition||
Treatment of chronic lymphocytic leukaemia
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.